Santamaría A. Prevención y t ratamiento del TEV en el embarazo y su relación con las complicaciones obstét ricas. Regist ro español (seguridad de t inzaparina). Comunicación XXIV Congreso Nacional SETH. Murcia, 23-25 de octubre de 2008.
Rodgers GM. Role of ant ithrombin concent rate in t reatment of hereditary ant ithrombin defi ciency. Thromb Haemost . 2009; 101:806-12.
Maclean PS, Tait RC. Hereditary and acquired ant ithrombin defi ciency: epidemiology, patogenesis and t reatment opt ions. Drugs. 2007;67:1429-40.
Kot tke-Marchant K, Duncan A. Ant ithrombin defi ciency: issues in laborat ory diagnosis. Arch Pat hol Lab Med. 2002;126: 1326-36.
Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J; American College of Chest Physicians. Venous thromboembolism, thrombophilia, ant ithrombot ic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Pract ice Guidelines (8 th Edit ion). Chest . 2008;133 Suppl 6:S844-86.
Folkeringa N, Brouwer JLP, Korteweg FJ, Veeger NJGM, Erwich JJHM, Van der Meer J. High risk of pregnancy-related venous thromboembolism in women with mult iple thrombophilic defects. Br J Haematol. 2007;138:110-6.
Navarro H, Morera J. Los ant iconcept ivos orales: criterios de selección, ut ilización y manej o. Inf Ter Sist Nac Salud. 1997;21: 1-10.
Pet it t i DB. Clinical pract ice. Combinat ion est rogen-progest in oral cont racept ives. N Engl J Med. 2003;349:1443-50.
Royal College of Obstet ricians and Gyneacologits. Thromboembolic disease in pregnancy and puerperium: acute management . Green-Top Guideline. 2007;28:4-17.
Blondel-Hill E, Mant MJ. The pregnant ant ithrombin III defi cient pat ient : management without ant it rhombin III concent rate. Thromb Res. 1992;65:193-8.